Gerresheimer’s Reckoning: Rejected Buyout, BaFin Scrutiny, and a Race for Credibility

The Düsseldorf-based pharmaceutical packaging group Gerresheimer is navigating one of the most turbulent periods in its history, juggling a spurned takeover approach, a deepening accounting probe, and its ejection from a key German stock index. The company’s decision to walk away from a near-100% premium bid has set the stage for a high-stakes turnaround that hinges on cleaning up its books and offloading a US subsidiary.

A Bold Rejection

In March, US packaging giant Silgan made an informal approach, valuing Gerresheimer shares at €41 apiece — roughly double the prevailing market price at the time. The offer was swiftly rebuffed. According to people familiar with the matter, management wants to first resolve its accounting irregularities and push ahead with the sale of its Centor unit before entertaining any dealmaking.

The stock initially dipped 5% on news of the rejection but quickly recovered. At current levels around €21.14, the shares are down roughly 61% from a year ago — though they have clawed back about 43% from their February nadir. The February sell-off was brutal: a single-day plunge of around 30% on February 11, followed by further pressure from an expanded BaFin probe that pushed the stock to its lowest point since 2009.

The Accounting Quagmire

At the heart of the crisis lie multiple layers of accounting failures. Germany’s financial watchdog, BaFin, launched an investigation in September 2025 and widened its scope in early March 2026. The regulator has identified three specific problem areas: incorrectly reported lease liabilities, flawed useful-life assumptions for capitalized development costs, and unrecognized impairment charges in the Advanced Technologies segment, which carries a book value of nearly €197 million.

A separate BaFin review of the half-year 2025 report is also underway, focusing on potentially outdated risk disclosures, missing impairments, and improperly booked bill-and-hold transactions. Gerresheimer initially pushed back against the allegations but later acknowledged the accounting errors. Both KPMG and Grant Thornton are now reviewing the company’s 2024 and 2025 financial statements.

The fallout has been severe. The Q1 2026 trading update has been postponed indefinitely, and the annual general meeting, originally scheduled for June 3, has been pushed back. The audited 2025 annual report is now expected in June 2026, with the half-year report following on July 14.

Should investors sell immediately? Or is it worth buying Gerresheimer?

Index Exit and Investor Chill

Since April 10, Gerresheimer is no longer a member of the SDAX, Germany’s small-cap index. The rules require companies to file their audited annual report within four months of the fiscal year-end — a deadline Gerresheimer missed after its fiscal year closed at the end of November 2025.

Until a certified set of accounts is published, the true financial picture remains opaque. The company’s 2026 guidance — revenue of €2.3 billion to €2.4 billion and an adjusted EBITDA margin of 18% to 19% — stands on shaky ground. Management insists the day-to-day business is running in line with expectations and that order books are solid, but institutional investors are likely to stay on the sidelines until the June accounts provide clarity.

Breathing Room from Lenders

Creditors representing 96% of Gerresheimer’s €870 million Schuldschein loan volume have agreed to extend maturities until September 30, 2026. Banking partners have followed suit, and key financial covenants related to leverage ratios have been waived through the end of the third quarter of 2026.

The company is also pushing ahead with the sale of Centor, its US unit specializing in packaging for prescription drugs. Morgan Stanley is running the process, and a double-digit number of interested parties have already emerged. Gerresheimer aims to complete the sale within 2026. Separately, it plans to shutter a glass factory in Chicago by the end of next year.

What Comes Next

The immediate calendar is unforgiving. The audited annual report is due in June, followed by the half-year report on July 14. BaFin will publish its findings publicly, though no timeline has been set for that decision.

For now, Gerresheimer is betting that fixing its balance sheet and streamlining its operations will restore investor confidence faster than accepting a buyout. Whether that gamble pays off depends on whether the June accounts deliver the clarity the market is demanding — or reveal deeper cracks still hidden beneath the surface.